Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric Phase 1/2 study of entrectinib in advanced solid and CNS tumors
2019-001155-39Phase 2Unknown
- Sponsor
- Roche
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of entrectinib in Non-hematologic malignancy and central nervous system tumor (2 arms), sponsored by Roche. Primary endpoint: Dose limiting toxicity of entrectinib. Status: unknown.
02
Drugs
entrectinib
03
Conditions
Non-hematologic malignancycentral nervous system tumor
Beyond the preview
Go deeper on 2019-001155-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001155-39.